📊 XCUR Key Takeaways
Is Exicure, Inc.. (XCUR) a Good Investment?
Exicure is a pre-revenue pharmaceutical company with severe financial distress: zero revenue, -$8.6M annual operating cash burn, and only ~5 months of cash runway at current burn rates. High debt-to-equity (1.75x) severely constrains financing flexibility. Company faces imminent existential risk without immediate revenue generation or significant capital injection.
Why Buy Exicure, Inc.. Stock? XCUR Key Strengths
- Current ratio of 1.19x provides minimal short-term liquidity buffer
- Cash position of $3.7M provides 4-6 months operational runway
- Early-stage biotech may have valuable intellectual property or pipeline assets not reflected in current financials
XCUR Stock Risks: Exicure, Inc.. Investment Risks
- Zero revenue with no evidence of near-term commercialization
- Severe cash burn of -$8.6M annually against minimal cash reserves creates existential solvency risk
- High leverage (1.75x debt-to-equity ratio) limits access to capital markets for additional financing
- Negative ROE (-126%) and ROA (-35.2%) demonstrate capital destruction
- Pharmaceutical sector requires sustained R&D spending; current cash position unsustainable
- Potential shareholder dilution imminent given financing needs
Key Metrics to Watch
- Quarterly cash burn rate and cash runway remaining
- Debt refinancing announcements and covenant compliance status
- Capital raise announcements or new financing terms
- Revenue recognition milestones or partnership deals
- Form 4 insider trading activity (sell-offs signal distress)
Exicure, Inc.. (XCUR) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Exicure, Inc.. presents a mixed fundamental picture. Review the detailed metrics above to form your own investment thesis.
XCUR Profit Margin, ROE & Profitability Analysis
XCUR vs Healthcare Sector: How Exicure, Inc.. Compares
How Exicure, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Exicure, Inc.. Stock Overvalued? XCUR Valuation Analysis 2026
Based on fundamental analysis, Exicure, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Exicure, Inc.. Balance Sheet: XCUR Debt, Cash & Liquidity
XCUR Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Exicure, Inc..'s revenue has declined by 61% over the 5-year period, indicating business contraction. The most recent EPS of $-4.75 indicates the company is currently unprofitable.
XCUR Revenue Growth, EPS Growth & YoY Performance
XCUR Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$600.0K | $-0.33 |
| Q2 2025 | N/A | $389.0K | $0.06 |
| Q1 2025 | N/A | -$829.0K | $-0.48 |
| Q3 2024 | N/A | -$600.0K | $-0.57 |
| Q2 2024 | N/A | -$600.0K | $-0.07 |
| Q1 2024 | N/A | -$829.0K | $-0.10 |
| Q2 2021 | $79.0K | $1.2M | $-0.04 |
| Q1 2021 | $997.0K | $1.2M | $0.01 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Exicure, Inc.. Dividends, Buybacks & Capital Allocation
XCUR SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Exicure, Inc.. (CIK: 0001698530)
📋 Recent SEC Filings
❓ Frequently Asked Questions about XCUR
What is the AI rating for XCUR?
Exicure, Inc.. (XCUR) has an AI rating of STRONG SELL with 92% confidence, based on fundamental analysis of SEC EDGAR filings.
What are XCUR's key strengths?
Claude: Current ratio of 1.19x provides minimal short-term liquidity buffer. Cash position of $3.7M provides 4-6 months operational runway.
What are the risks of investing in XCUR?
Claude: Zero revenue with no evidence of near-term commercialization. Severe cash burn of -$8.6M annually against minimal cash reserves creates existential solvency risk.
What is XCUR's revenue and growth?
Exicure, Inc.. reported revenue of $0.0.
Does XCUR pay dividends?
Exicure, Inc.. does not currently pay dividends.
Where can I find XCUR SEC filings?
Official SEC filings for Exicure, Inc.. (CIK: 0001698530) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is XCUR's EPS?
Exicure, Inc.. has a diluted EPS of $-0.79.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is XCUR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Exicure, Inc.. has a STRONG SELL rating with 92% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is XCUR stock overvalued or undervalued?
Valuation metrics for XCUR: ROE of -126.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy XCUR stock in 2026?
Our dual AI analysis gives Exicure, Inc.. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is XCUR's free cash flow?
Exicure, Inc..'s operating cash flow is $-8.6M, with capital expenditures of $1.0K.
How does XCUR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -126.0% (avg: 15%), current ratio 1.19 (avg: 2).
Is Exicure, Inc.. carrying too much debt?
XCUR has a debt-to-equity ratio of 1.75x, which is above the Healthcare sector average of 0.6x. However, the current ratio of 1.19 suggests adequate short-term liquidity.